Recent genomic studies of neuroblastoma tumors using whole-genome sequencing have identified loss-of-function genetic alterations (somatic mutations, small indels, and single nucleotide variations) of ATRX, which encodes chromatin remodeling proteins in the telomeric region, in approximately 10% of patients with neuroblastoma (35), (36). The gene discussed is ATRX; the disease is neuroblastoma.